BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.67% | -61.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.52% | -51.44% | |||
| Operating Income | 35.52% | 51.44% | |||
| Income Before Tax | 144.51% | 29.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 144.51% | 29.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -570.31% | -91.52% | |||
| Net Income | 141.91% | 26.73% | |||
| EBIT | 35.52% | 51.44% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 139.08% | 29.84% | |||
| Normalized Basic EPS | 101.85% | 31.65% | |||
| EPS Diluted | 134.48% | 40.82% | |||
| Normalized Diluted EPS | 101.85% | 31.65% | |||
| Average Basic Shares Outstanding | 7.48% | 3.93% | |||
| Average Diluted Shares Outstanding | 21.84% | 3.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
